The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC).
 
Omar Alhalabi
No Relationships to Disclose
 
Nathaniel Wilson
No Relationships to Disclose
 
Neema Navai
No Relationships to Disclose
 
Matthew T Campbell
Honoraria - Apricity Health; Astellas Pharma; Axdev; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medscape; Pfizer; Seagen
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Exelixis; Genentech; Pfizer
Research Funding - Apricity Health (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Other Relationship - Bristol-Myers Squibb; Merck; Pfizer; Roche
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Janssen Biotech; Jounce Therapeutics; Pfizer; Seagen; Symphogen
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Paul G. Corn
Research Funding - Janssen Oncology (Inst)
 
Ana Aparicio
Honoraria - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc; Janssen Research & Development
Consulting or Advisory Role - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc.; Janssen Research & Development
Speakers' Bureau - Biosense Webster (I); Boston Scientific (I)
Research Funding - BioSense Webster (I); Boston Scientific (I); Bristol-Myers Squibb (Inst); Hansen Medical (I); Janssen (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Two (I)
Travel, Accommodations, Expenses - Biosense WEbster (I)
 
Bogdan Czerniak
No Relationships to Disclose
 
Charles Guo
No Relationships to Disclose
 
Christopher Logothetis
Honoraria - Amgen; Bayer; Exelixis; Merck Sharp & Dohme
Consulting or Advisory Role - Amgen; Bayer; Exelixis; Merck Sharp & Dohme
Research Funding - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Sanofi
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Ipsen; Lilly; Nektar; Pfizer; Surface Oncology
 
Seungtaek Choi
No Relationships to Disclose
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea; Bavarian Nordic; Bristol-Myers Squibb; EMD Serono; Genentech; Janssen; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.